Pediatric Cancer Program
(David G. Poplack M.D., Leader;
Ching Lau, M.D., Ph.D., Co-Leader)
This program, located in the Texas Children's Cancer Center, is an internationally recognized leader in childhood cancer research and involves 71 investigators who focus on both clinical and laboratory research.
The major themes of the center are to improve understanding of the biologic basis of pediatric cancer and to identify and develop improved methods of diagnosis, treatment and prevention. Laboratory research is largely molecular in nature and includes cancer genomic analysis of pediatric malignancies, molecular studies of cancer predisposition syndromes, investigation of cell cycle regulation in tumors and model organisms, tumor vaccine and immunology studies, identification of novel molecular targets and the development of innovative therapies. There is an integrated, comprehensive clinical research infrastructure that supports both intra-institutionally developed and cooperative group-initiated clinical trials.
Currently, we conduct or participate in 154 clinical trials, 68 of which are Cancer Center-initiated treatment studies.
A competitively awarded grant supports participation in the NCI-supported Children's Oncology Group. We are one of nine national centers funded by the NCI to participate in the Pediatric Brain Tumor Clinical Trial Consortium and one of thirteen NIH-funded Pediatric Pharmacology Research Units.
The TCCC has one of the largest pediatric oncology training programs in the nation and receives support for training pediatric oncology clinical researchers through an NIH K12 training grant. The TCCC is the site of the Childhood Cancer Epidemiology and Prevention Center, a joint center of Baylor College of Medicine and the MD Anderson Cancer Center, that pursues both population based and molecular epidemiology studies of childhood cancer. Cancer genetic studies are undertaken through participation in the NCI-supported Texas Cancer Genetics Consortium.